Core Insights - The 25th Cardiology Conference and the 2025 Henan Provincial Medical Association's Academic Annual Meeting on Electrophysiology and Pacing was held in Zhengzhou, focusing on cutting-edge technologies, clinical practices, and research achievements in the field of cardiology [1][3] Group 1: Conference Overview - The conference theme was "Seeing the Future of Heart Health in Henan, Smartly Designing the City of Rhythm," featuring nearly a thousand experts and scholars from both domestic and international backgrounds [3] - Over 100 sessions were organized, covering hot topics such as pulse ablation, artificial intelligence, and the integration of medicine and engineering [3][4] Group 2: Key Discussions and Innovations - The conference emphasized the importance of talent and technological innovation as core driving forces for the development of cardiology in China, with a call for professionals to transition from "catching up" to "leading" in the field [3] - Discussions included the popularization of catheter ablation technology and the decentralization of medical resources to grassroots levels, aiming to enhance precision diagnosis and treatment of arrhythmias [4] Group 3: Future Directions - A proposal was made to integrate resources from multiple medical societies over the next decade to create a high-quality evidence-based medicine platform, promoting the widespread adoption of atrial fibrillation ablation techniques in 2,000 county hospitals [4] - The conference aimed to facilitate a systematic agenda covering basic research, clinical practice, technology transfer, and interdisciplinary collaboration, fostering deep exchanges between clinical experience and research innovation [4]

Core Viewpoint - Arrhythmia is a significant cause of mortality in cardiovascular diseases, and traditional Chinese medicine (TCM) plays an irreplaceable role in its prevention and treatment, with the product "Shensong Yangxin Capsule" being a notable example due to its strong evidence-based medical support and high recommendations in clinical guidelines [1][13]. Group 1: Clinical Research and Efficacy - The "Shensong Yangxin Capsule" was recognized in a study published in the "European Heart Journal," showing that it can reduce the risk of atrial fibrillation recurrence by 40.4% after one year in patients who underwent radiofrequency ablation [2][5]. - Six evidence-based medical studies have confirmed the efficacy of "Shensong Yangxin Capsule" in treating various arrhythmias, including premature ventricular contractions and atrial fibrillation, demonstrating its advantages in integrated regulation [4][13]. - The capsule has been shown to significantly reduce the frequency of premature ventricular contractions and improve heart function in patients with heart failure [4][6]. Group 2: Guidelines and Recommendations - Multiple expert consensus and guidelines recommend "Shensong Yangxin Capsule" for treating arrhythmias, highlighting its comparable efficacy and better safety profile compared to conventional drugs like Propafenone and Mexiletine [5][6][8]. - The capsule is the only innovative TCM recommended for symptomatic premature ventricular contractions in the "Chinese Expert Consensus on Ventricular Arrhythmias" [6][7]. - For patients with heart failure and ventricular arrhythmias, the guidelines suggest considering "Shensong Yangxin Capsule" to reduce the burden of premature ventricular contractions and improve cardiac function [7][10]. Group 3: Broader Implications and Future Prospects - "Shensong Yangxin Capsule" is positioned as an essential innovative TCM in the treatment of arrhythmias, showcasing the value of TCM in modern medicine [13]. - The ongoing development of high-quality evidence-based research is expected to further enhance the benefits of "Shensong Yangxin Capsule" for patients [13].

Core Viewpoint - The research team led by Liu Hui and Xu Chang has introduced a novel methodology called "evidence contamination," which aims to address biases in randomized controlled trials (RCTs) and improve the reliability of evidence in clinical guidelines [1][3][4]. Group 1: Research Findings - The team identified 1,300 problematic trials and tracked 847 evidence studies containing these trials, leading to the discovery that 20.6% of evidence conclusions changed when problematic trials were excluded [3][4]. - At least 157 international clinical guidelines were found to be influenced by these problematic conclusions, indicating a cascading effect on global medical evidence [3][4]. Group 2: Implications for Clinical Guidelines - The findings highlight significant discrepancies in clinical guidelines, such as those for the treatment of advanced liver cancer, where the National Comprehensive Cancer Network (NCCN) and the European Association for the Study of the Liver (EASL) have conflicting recommendations [3]. - The research emphasizes the need for a new approach to clinical guideline decision-making, as current practices may lead to serious medical adverse events due to unreliable evidence [3][4]. Group 3: Recognition and Future Directions - The research has been published in The BMJ, marking the first time an original theory from Chinese scholars has been featured in the journal's 180-year history, showcasing China's contributions to medical research methodology [1][5]. - The establishment of the Asia-Pacific Network for Evidence Analysis, Synthesis, and Translation (APN-EAST) aims to enhance global collaboration in evidence-based medicine and develop a system for assessing and preventing evidence contamination [5].

Core Concept - The article highlights the significant impact of evidence-based medicine (EBM) in transforming medical practices in China, primarily through the efforts of Wang Jiyao, who introduced and promoted EBM in the country [3][15][26]. Group 1: Introduction of Evidence-Based Medicine - Wang Jiyao was influenced by her mentor David Sackett during her studies in Canada, where she learned the importance of evidence in medical treatment [2][4]. - EBM, defined by five steps, emphasizes the necessity of using evidence rather than solely relying on personal experience in medical practices [2][3]. Group 2: Development and Promotion in China - After returning to China, Wang Jiyao translated EBM into Chinese and began promoting it, leading to significant advancements in modern medicine over nearly 30 years [3][15]. - The publication of the first EBM textbook in China in 2001 filled a gap in the field and has been revised multiple times to include updated methodologies and standards [23][24]. Group 3: Current Challenges and Future Directions - Despite the growth in clinical research and guidelines, there are concerns regarding the quality of these guidelines, with many lacking proper evaluation and facing conflicts of interest [29][31]. - The establishment of the China Clinical Practice Guidelines Alliance aims to improve the quality of clinical guidelines by uniting top experts to create reliable and practical recommendations for clinicians [33][34][41].